Skip to content

AstriVax Therapeutics

Active Public limited companyfounded 2022active for 4 yearsGaston Geenslaan 3, 3001 LeuvenKBO/BCE: BE 0787.990.881

Lifetime

3 annual accounts with figures on one time axis
peak of -€5.3m in 2023
-not published
lowest -€8.2m in 2024
-€7.7m▲ €540,602
peak of €18.3m in 2024
€10.7m▼ 41.7%
€1.8m▼ 42.0%
peak of 19.5 FTE in 2024
17.1 FTE▼ 12.3%
Board11 names since 2022
9 directors and 8 others
Owners3 names in the annual accounts
17.16% and 1 other
Documentsfilings and deeds
21-05-202671 days before the deadline
2025financial year
Loss of €7.7mStaff from 19.5 FTE to 17.1 FTECapital decrease to €15,770,445.92 19-06Company renamed from AstriVax to AstriVax Therapeutics 28-03 resigns as director 07-02Equity from €18.3m to €10.7m

Key points

from the 2025 annual accounts

Equity

€10.7m ▼ 41.7%
€18m2024€11m2025

Equity fell in 2025 from €18.3m to €10.7m.

Losses

-€22.6m in three years
-6.72023-8.22024-7.72025

Every financial year from 2023 to 2025 closed with a loss. 2024 was the heaviest.

Staff

12 employees on 31-12-2025
1812023952024092025

In 2025, nobody joined and 9 employees left.

Payment terms

38 days to suppliers
Suppliers
59 to 38

AstriVax Therapeutics pays its suppliers 21 days earlier than in 2024.

Position in the sector

-€7.7m

Lower net result than 91% of companies in research and development. The sector median is €55,995, over 120 companies.

Public support

€5.9m awarded from 2022 to 2025
2022202320242025

AstriVax Therapeutics was awarded €5.9m in Flemish support from 2022 to 2025, mostly under Onderzoeksproject.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 132 companies had the same profile as AstriVax Therapeutics has now. Each dot is one company, two years later.

93.2%
were still trading
3.8%
stopped another way
3.0%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 132 companies, not a prediction for AstriVax Therapeutics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 15-07-2022
Director,
Director, since 15-07-2022
Director, since 15-07-2022
Director, since 15-07-2022
Auditor,
and 4 others
  • 17.16%equity €124.0m (2025) · annual accounts 2025 of +
  • 14.3%score equity €30.4m (2025) · annual accounts 2025 of
  • 14.3%score equity €51.8m (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0787990881
Capital decrease to €15,770,445.92 The capital fell from €26,546,226.67 to €15,770,445.92 · appointed as director · General meeting of 10-06-2025 · Gazette deed
Company renamed from AstriVax to AstriVax Therapeutics General meeting of 18-03-2025 · Gazette deed
resigns as director appointed as director · Board meeting of 01-10-2024 · Gazette deed
All 14 events

Comparable companies

same main activity, similar in size and age
Company
AstriVax Therapeutics Leuven €12.5m - 85.3% 17.1
Protealis Ghent €11.1m €1.1m 81.5% 17.2
AmphiStar Ghent €10.1m €2.1m 63.2% 13.5
Microbial Resource Management Health Ghent €11.7m €0.8m 59.2% 22.8
Cryptobiotix Ghent €5.7m €3.9m 64.9% 15.8
Natural Plant based Solutions Bree €9.4m -€0.1m -28.3% 10.2
TripleW Antwerp €18.1m €2.4m 42.9% 13

These companies have the same main activity as AstriVax Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €5.7m and €18m, founded between 2019 and 2021.

Official details

Source: KBO
Status
Active since 04-07-2022Normal situation
Registered office
14 active companies are registered at this addressOf these, 2 started in the 12 months before 19 November 2026. Source: KBO register, as of 19 November 2026.
Activity
Research and development on biotechnologyNACE 72101
Joint committee
207White-collar workers in the chemical industry · annual accounts 2025
Establishment unit
2.334.105.7533001 Leuven, since 04-07-2022
Financial year end
31 December
Peppol
Reachable since 21-10-2026
Company details

Annual accounts 2025

€12.5m▼ 41.8%
Employeeson 31-12-2025
12▼ 42.9%
Filing
Filed on 21-05-2026, 71 days before the end of the filing period
Financials

Insights on AstriVax Therapeutics

The annual accounts of AstriVax Therapeutics for financial year 2025 show a net loss of 61% of total assets. The 2025 annual accounts show equity of €10.7m and a net result of -€7.7m.

Equity has been shrinking by about 14% per year since 2023. Its solvency ranks better than 81% of 121 sector peers (NACE 72) in financial year 2025.

The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about AstriVax Therapeutics

What is the company number of AstriVax Therapeutics?
The company number of AstriVax Therapeutics is 0787.990.881. The VAT number is the same number with BE in front: BE 0787.990.881.
Where is AstriVax Therapeutics based?
The registered office is at Gaston Geenslaan 3, 3001 Leuven.Company details
What does AstriVax Therapeutics do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of AstriVax Therapeutics?
AstriVax Therapeutics is a public limited company (NV).
When was AstriVax Therapeutics founded?
AstriVax Therapeutics was founded on 04-07-2022.
Is AstriVax Therapeutics still active?
Yes, AstriVax Therapeutics is an active enterprise in the KBO register.
How many employees does AstriVax Therapeutics have?
AstriVax Therapeutics had an average of 17.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does AstriVax Therapeutics fall under?
In its 2025 annual accounts, AstriVax Therapeutics states joint committee 207 (White-collar workers in the chemical industry).
What is the turnover of AstriVax Therapeutics?
The annual accounts for financial year 2025 state no turnover.
Is AstriVax Therapeutics profitable?
In financial year 2025, AstriVax Therapeutics made a loss of €7.7m.
Where can I find the annual accounts of AstriVax Therapeutics?
AstriVax Therapeutics filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of AstriVax Therapeutics due?
AstriVax Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.